About
Vaccines & Immunotherapy
Areas of Focus
Categories
Biologics & BiopharmaceuticalVaccine
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
5
As Collaborator
4
Total Enrollment
12,835
By Phase
PHASE2: 4PHASE3: 1PHASE1/PHASE2: 2PHASE1: 1
By Status
COMPLETED: 5RECRUITING: 3UNKNOWN: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06272812Collaborator
A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region.
PHASE2Recruiting
4,300 participants
Started: Feb 19, 2025 · Completed: Mar 31, 2028
NCT05947890Collaborator
Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa
PHASE2Recruiting
276 participants
Started: Jan 30, 2024 · Completed: Feb 2, 2026
NCT04975178Lead Sponsor
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
PHASE3Recruiting
7,120 participants
Started: Oct 17, 2022 · Completed: Feb 28, 2029
NCT03982797Lead Sponsor
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis
PHASE2Unknown
306 participants
Started: May 17, 2019 · Completed: Mar 3, 2022
NCT03536117Lead Sponsor
Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates
PHASE2Completed
99 participants
Started: Feb 12, 2019 · Completed: May 17, 2022
Locations (1)
Headquarters
Pontevedra, Spain
Map
Loading map...